Puzoo Medical’s "multi-target closed-loop + AI" strategy bridges precision and access in neuromodulation

In the past decade, neuroscience has been accelerating its transition from fundamental research to industrial application. Emerging fields such as non-invasive neuromodulation, digital therapeutics, and brain-computer interfaces (BCI) are driving technological innovation and clinical transformation within the realm of brain health. Data from Precedence Research (2024) shows that the global Digital Brain Health market has reached a scale of 231.1 billion USD and is projected to grow to 476.8 billion USD by 2034, representing a compound annual growth rate (CAGR) of 7.5%.

Behind this rapid market growth lies the fact that brain disorders have become a significant global public health burden. Currently, the number of patients with functional brain disorders, such as depression, Parkinson's disease, and autism spectrum disorder, continues to rise. Taking depression as an example, World Health Organization (WHO) data indicates that the global prevalence of depression among adults is approximately 5.7%. According to data from the Chinese Center for Disease Control and Prevention, about 95 million people in China are affected by depression. Annually, there are approximately 280,000 suicides in China, with about 40% of them related to depression. These diseases not only cause immense physical and psychological suffering to individuals but also impose enormous social and economic burdens.

However, conventional treatment methods still struggle to meet the vast clinical demand. Chemical drugs are limited by the blood-brain barrier, making it difficult for them to act precisely on the central nervous system, and they are often accompanied by side effects such as cognitive decline and dependency. Surgical interventions, such as Deep Brain Stimulation (DBS), have proven efficacy but are currently established for only a limited number of indications like Parkinson's disease, due to their invasive nature, high cost, and significant risks.

Liu Ping, Deputy General Manager of Puzoo Medical, stated: "Currently, about 80% of patients still face the reality of limited access to effective treatment." In her view, the industry urgently requires a new intervention method that combines safety, precision, and accessibility—one that can overcome the dual limitations of drugs and surgery while adapting to the rehabilitation needs of different populations and various disease stages.

Puzoo Medical has chosen to focus on "Physical Neuromodulation + AI" as its technological core, exploring a new pathway for translating neuroscience from fundamental research into clinical application.

Puzoo Medical was founded in 2021 and is located in the Intelligent Manufacturing Industrial Park in Nanchang, Jiangxi province. The founding team has deep roots in neuromodulation research and, through clinical practice, observed that such technologies can significantly improve patients' emotional, motor, or cognitive states, which led them to embark on an industrial exploration path. Compared to more invasive and higher-risk brain-computer interface (BCI) approaches with longer development cycles, this direction better balances safety and accessibility, aligning with market demand for "non-invasive and precise" treatments.

From the early stages of its venture, Puzoo Medical has focused on three specific demographic groups: the elderly, children, and women. The reason is that these populations exhibit a high incidence of functional brain disorders yet have long faced a shortage of high-quality treatment resources. Puzoo Medical aims to enhance treatment accessibility for these groups through more affordable and readily available technological solutions, enabling more patients to benefit.

Centered on this mission, Puzoo Medical rapidly transitioned from technology validation to industrial implementation. In 2022, the company's first Transcranial Magnetic Stimulation (TMS) device received market approval. By 2024, Puzoo Medical was recognized as a National High-Tech Enterprise and a Specialized and Sophisticated Enterprise. In 2025, its multi-target TMS device was listed in the Jiangxi Provincial Catalogue for the Promotion of Major Technological Equipment (First Set). The company's products are now used in over 400 medical institutions across China, serving mainstream departments such as Rehabilitation Medicine, Neurology, and Psychiatry, and extending into Pediatrics and Gynecology & Obstetrics to meet the diverse rehabilitation needs of different populations.

Behind these technological breakthroughs is a team that equally values research and engineering. The digital therapeutics team collaborates with Central China Normal University to advance rehabilitation solutions integrating "AI + special education." The electronic medicine team focuses on the engineering application of physical neuromodulation technologies based on "magnetic, electrical, acoustic, and optical" principles.

In its commercial operations, Puzoo Medical places great emphasis on regulatory compliance. From the product design phase, the company considers healthcare policy compliance, ensuring that device names and indications align with the national medical insurance reimbursement catalog. Currently, the fees for most of Puzoo Medical's products are covered by the medical insurance catalogs of most provinces. The company holds ISO 13485 and ISO 9001 Quality Management System certifications, allocates over 40% of its expenditure to research and development, and funds ongoing technological advancements and product expansion through its own capital.

Regarding international expansion, Puzoo Medical has chosen to start in Southeast Asia, Latin America, and countries along the Belt and Road Initiative. These regions generally recognize Chinese regulatory certifications and ISO standards, allowing for quicker market entry. The company has achieved its first breakthrough in international markets. Currently, Puzoo Medical is collaborating with international distributors and plans to pursue FDA and CE certifications to enter the high-end markets of Europe and the United States.

In the process of industrializing brain science, non-invasive neuromodulation is recognized as one of the most promising technological pathways. However, achieving precise and controllable intervention in brain activity under the premise of "non-invasiveness" remains a critical challenge for the entire industry. Traditional Transcranial Magnetic Stimulation (TMS) devices typically employ single-target output, making it difficult to address deep neural circuit modulation and lacking the capability for personalized parameter adjustment.

Puzoo Medical has established an integrated dual-component technological framework of "multi-target synchronous modulation and AI closed-loop intelligent platform," advancing neuromodulation from single-point activation toward network-level synergy.

At the core of this system lies multi-target closed-loop modulation technology, which achieves four-pulse sequence control with millisecond precision. Through modular power supply design and pulse algorithm optimization, the device can simultaneously act on up to four central and peripheral targets. For instance, in spinal cord injury rehabilitation, the system automatically matches stimulation intervals based on neuronal conduction velocity. If a neural signal takes approximately 25 milliseconds to travel from point A to point B, the system sets the inter-target interval at 25 milliseconds to simulate neural transmission. This approach of "delivering the right stimulus at the right target with the correct timing interval" ensures that electromagnetic signals align more closely with the physiological principles of neural plasticity.

Schematic Diagram of Multi-Target Closed-Loop Control Device

Building upon its multi-target technology, Puzoo Medical integrates adaptive AI algorithms to form a closed-loop system encompassing diagnosis, treatment, and monitoring. The system can collect real-time physiological data, such as electroencephalogram (EEG), from patients and dynamically adjust intervention protocols based on their current status and disease progression, thereby establishing a truly adaptive closed loop throughout the treatment process.

Leveraging this technological framework, Puzoo Medical has developed a comprehensive product matrix that covers multiple physical neuromodulation modalities, including magnetic, electrical, and acoustic-optical approaches, providing integrated solutions for clinical screening, diagnosis, and treatment.

Within its magnetic product line, the flagship navigated Transcranial Magnetic Stimulation (TMS) system incorporates multi-target closed-loop modulation technology and has been widely applied in conditions such as depression, Parkinson's disease, and post-stroke rehabilitation. Additionally, the portfolio includes specialized devices such as pediatric TMS systems designed for children and pelvic floor magnetic stimulators focused on pelvic floor rehabilitation. The electrical product range covers transcranial electrical stimulation, ocular electrical stimulation, and non-invasive spinal electrical stimulation. Among these, the portable home-use transcranial electrical stimulator targets individuals with mild cognitive impairment and postpartum depression, supporting home-based rehabilitation and remote data transmission to ensure consistency between in-hospital and out-of-hospital treatment. Devices such as the electroencephalogram therapy device (A620) and closed-loop electrical stimulation systems further support the EEG monitoring and AI-assisted diagnostic closed-loop framework. In the acoustic-optical category, the company offers transcranial ultrasound products, enriching its multimodal stimulation solutions. Meanwhile, Puzoo Medical's in-development EEG monitoring and AI-assisted diagnostic system continues to enhance its intelligent closed-loop ecosystem of "stimulation–monitoring–adjustment."

Overall, with multi-target closed-loop technology as its core technical foundation, Puzoo Medical combines precise in-hospital therapeutic devices with home-based rehabilitation management products. By deeply integrating physical neuromodulation methods with adaptive AI algorithms, the company achieves millimeter-level precision positioning and dynamic closed-loop intervention while expanding clinical accessibility through medical insurance compatibility and cost optimization. Ultimately, this approach enables the establishment of a full-cycle neuromodulation ecosystem, realizing both precision and accessibility in neurological treatment.

Puzoo Medical is establishing a full-cycle neuromodulation ecosystem that spans from in-hospital precision treatment to at-home rehabilitation management, providing a systematic pathway for the industrialization of non-invasive brain science.

Two years ago, Puzoo Medical obtained regulatory approval for its home-use transcranial electrical stimulator. The team is currently advancing the miniaturization and intelligent upgrading of the device—reducing the size of portable units, simplifying the user interface, and building a cloud-based system to enable data synchronization between in-hospital and out-of-hospital settings, ensuring consistent therapeutic efficacy.

At the same time, Puzoo Medical is strategically deploying technologies across the entire cycle of "screening–intervention–rehabilitation," developing brain function monitoring devices to assist in early screening and creating a TMS-EEG multimodal closed-loop solution to achieve real-time integration of "stimulation–monitoring–adjustment." Additionally, AI-powered special education products that combine EEG signals with behavioral data are set to be launched soon.

Based on this strategic direction, Puzoo Medical has defined clear development goals. In the short term, over the next 2–3 years, it plans to expand its regulatory approvals to 10 items and position itself among the top tier in the field of non-invasive brain-computer interfaces. In the long term, the company aims to promote the domestic localization of core technologies in China, striving to reduce equipment costs by over 30% and make high-end neuromodulation products accessible to grassroots communities and households.